Literature DB >> 35440740

Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.

Anja Karlstaedt1, Javid Moslehi2, Rudolf A de Boer3.   

Abstract

Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology has revealed that these seemingly disparate disease processes are intertwined, owing to the cardiovascular sequelae of anticancer therapies, shared risk factors that predispose individuals to both cardiovascular disease and cancer, as well the possible potentiation of cancer growth by cardiac dysfunction. As a result, interest has increased in understanding the fundamental biological mechanisms that are central to the relationship between cardiovascular disease and cancer. Metabolism, appropriate regulation of energy, energy substrate utilization, and macromolecular synthesis and breakdown are fundamental processes for cellular and organismal survival. In this Review, we explore the emerging data identifying metabolic dysregulation as an important theme in cardio-oncology. We discuss the growing recognition of metabolic reprogramming in cardiovascular disease and cancer and view the novel area of cardio-oncology through the lens of metabolism.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35440740     DOI: 10.1038/s41569-022-00698-6

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  187 in total

Review 1.  Cardiovascular Toxic Effects of Targeted Cancer Therapies.

Authors:  Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

2.  Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart.

Authors:  Anja Karlstaedt; Xiaotian Zhang; Heidi Vitrac; Romain Harmancey; Hernan Vasquez; Jing Han Wang; Margaret A Goodell; Heinrich Taegtmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-31       Impact factor: 11.205

3.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

4.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

5.  Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.

Authors:  Daniel A Mulrooney; Mark W Yeazel; Toana Kawashima; Ann C Mertens; Pauline Mitby; Marilyn Stovall; Sarah S Donaldson; Daniel M Green; Charles A Sklar; Leslie L Robison; Wendy M Leisenring
Journal:  BMJ       Date:  2009-12-08

Review 6.  Common risk factors for heart failure and cancer.

Authors:  Wouter C Meijers; Rudolf A de Boer
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

7.  Cardiovascular Risk Factors are Associated with Future Cancer.

Authors:  Emily S Lau; Samantha M Paniagua; Elizabeth Liu; Manol Jovani; Shawn X Li; Katherine Takvorian; Navin Suthahar; Susan Cheng; Greta L Splansky; James L Januzzi; Thomas J Wang; Ramachandran S Vasan; Bernard Kreger; Martin G Larson; Daniel Levy; Rudolf A de Boer; Jennifer E Ho
Journal:  JACC CardioOncol       Date:  2021-03-16

8.  D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.

Authors:  Esra A Akbay; Javid Moslehi; Camilla L Christensen; Supriya Saha; Jeremy H Tchaicha; Shakti H Ramkissoon; Kelly M Stewart; Julian Carretero; Eiki Kikuchi; Haikuo Zhang; Travis J Cohoon; Stuart Murray; Wei Liu; Kazumasa Uno; Sudeshna Fisch; Kristen Jones; Sushma Gurumurthy; Camelia Gliser; Sung Choe; Marie Keenan; Jaekyoung Son; Illana Stanley; Julie A Losman; Robert Padera; Roderick T Bronson; John M Asara; Omar Abdel-Wahab; Philip C Amrein; Amir T Fathi; Nika N Danial; Alec C Kimmelman; Andrew L Kung; Keith L Ligon; Katharine E Yen; William G Kaelin; Nabeel Bardeesy; Kwok-Kin Wong
Journal:  Genes Dev       Date:  2014-03-01       Impact factor: 11.361

Review 9.  Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.

Authors:  Joseph Pierre Aboumsallem; Javid Moslehi; Rudolf A de Boer
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501

10.  Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Rudolf A de Boer; Jean-Sébastien Hulot; Carlo Gabriele Tocchetti; Joseph Pierre Aboumsallem; Pietro Ameri; Stefan D Anker; Johann Bauersachs; Edoardo Bertero; Andrew J S Coats; Jelena Čelutkienė; Ovidiu Chioncel; Pierre Dodion; Thomas Eschenhagen; Dimitrios Farmakis; Antoni Bayes-Genis; Dirk Jäger; Ewa A Jankowska; Richard N Kitsis; Suma H Konety; James Larkin; Lorenz Lehmann; Daniel J Lenihan; Christoph Maack; Javid J Moslehi; Oliver J Müller; Patrycja Nowak-Sliwinska; Massimo Francesco Piepoli; Piotr Ponikowski; Radek Pudil; Peter P Rainer; Frank Ruschitzka; Douglas Sawyer; Petar M Seferovic; Thomas Suter; Thomas Thum; Peter van der Meer; Linda W Van Laake; Stephan von Haehling; Stephane Heymans; Alexander R Lyon; Johannes Backs
Journal:  Eur J Heart Fail       Date:  2020-11-12       Impact factor: 15.534

View more
  1 in total

1.  Targeted therapies for cardiac diseases.

Authors:  Christoph Maack; Jil C Tardiff
Journal:  Nat Rev Cardiol       Date:  2022-06       Impact factor: 49.421

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.